Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ
Closed
Sep 18, 2026
Day's Range
8.4052 wk Range
2.29Overview - ARTV - Artiva Biotherapeutics, Inc.
Key Statistics
Valuation
Enterprise Value
73.08M
P/E (Trailing)
‪-2.45‬
P/E (Forward)
‪-3.23‬
PEG Ratio
‪0.08‬
Price / Book
‪1.18‬
EV / EBITDA
‪-0.78‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-22.33%‬
Return on Equity
‪-36.58%‬
Ownership
Shares Outstanding
48.88M
Float
19.58M
Short % of Shares Outstanding
‪5.35%‬
Held by Insiders
‪14.81%‬
Held by Institutions
‪84.13%‬
Price stats
Beta
‪2.19‬
50-Day Avg
‪10.62‬
200-Day Avg
‪7.64‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
6 analysts
Average price target
‪$ 35.80‬Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - ARTV - Artiva Biotherapeutics, Inc.
Peers - ARTV - Artiva Biotherapeutics, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- ARTVNASDAQArtiva Biotherapeutics, Inc. Common Stock412.63MMarket Cap+65.88%52-week change-2.45P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE61.58BMarket Cap+25.27%52-week change37.92P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.32.05BMarket Cap-91.57%52-week change41.68P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE24.13BMarket Cap-2.77%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.57BMarket Cap+17.02%52-week change18.34P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.13.02BMarket Cap+22.62%52-week change-17.62P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.12.37BMarket Cap+15.64%52-week change172.81P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - ARTV - Artiva Biotherapeutics, Inc.
About
Artiva Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Its lead product candidate, AlloNK, is an allogeneic, off-the-shelf, cryopreserved NK cell therapy designed to enhance the…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
